全文获取类型
收费全文 | 961篇 |
免费 | 180篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
妇产科学 | 8篇 |
基础医学 | 72篇 |
口腔科学 | 1篇 |
临床医学 | 21篇 |
内科学 | 33篇 |
皮肤病学 | 1篇 |
神经病学 | 10篇 |
特种医学 | 3篇 |
外科学 | 893篇 |
综合类 | 67篇 |
预防医学 | 4篇 |
眼科学 | 7篇 |
药学 | 19篇 |
中国医学 | 2篇 |
肿瘤学 | 12篇 |
出版年
2024年 | 1篇 |
2023年 | 12篇 |
2022年 | 5篇 |
2021年 | 20篇 |
2020年 | 37篇 |
2019年 | 40篇 |
2018年 | 39篇 |
2017年 | 36篇 |
2016年 | 37篇 |
2015年 | 57篇 |
2014年 | 51篇 |
2013年 | 57篇 |
2012年 | 39篇 |
2011年 | 44篇 |
2010年 | 57篇 |
2009年 | 38篇 |
2008年 | 43篇 |
2007年 | 62篇 |
2006年 | 53篇 |
2005年 | 51篇 |
2004年 | 76篇 |
2003年 | 67篇 |
2002年 | 42篇 |
2001年 | 43篇 |
2000年 | 34篇 |
1999年 | 35篇 |
1998年 | 17篇 |
1997年 | 13篇 |
1996年 | 24篇 |
1995年 | 11篇 |
1994年 | 8篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有1157条查询结果,搜索用时 0 毫秒
41.
42.
43.
Lars Burdorf Christopher T. Laird Donald G. Harris Margaret R. Connolly Zahra Habibabady Emily Redding Natalie A. O'Neill Arielle Cimeno Dawn Parsell Carol Phelps David Ayares Agnes M. Azimzadeh Richard N. Pierson 《American journal of transplantation》2022,22(1):28-45
Galactosyl transferase knock-out pig lungs fail rapidly in baboons. Based on previously identified lung xenograft injury mechanisms, additional expression of human complement and coagulation pathway regulatory proteins, anti-inflammatory enzymes and self-recognition receptors, and knock-down of the β4Gal xenoantigen were tested in various combinations. Transient life-supporting GalTKO.hCD46 lung function was consistently observed in association with either hEPCR (n = 15), hTBM (n = 4), or hEPCR.hTFPI (n = 11), but the loss of vascular barrier function in the xenograft and systemic inflammation in the recipient typically occurred within 24 h. Co-expression of hEPCR and hTBM (n = 11) and additionally blocking multiple pro-inflammatory innate and adaptive immune mechanisms was more consistently associated with survival >1 day, with one recipient surviving for 31 days. Combining targeted genetic modifications to the lung xenograft with selective innate and adaptive immune suppression enables prolonged initial life-supporting lung function and extends lung xenograft recipient survival, and illustrates residual barriers and candidate treatment strategies that may enable the clinical application of other organ xenografts. 相似文献
44.
First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes – Chapter 1: update on national regulatory frameworks pertinent to clinical islet xenotransplantation 下载免费PDF全文
Emanuele Cozzi Ralf R. Tönjes Pierre Gianello Léo H. Bühler Gina R. Rayat Shinichi Matsumoto Chung‐Gyu Park Ivo Kwon Wei Wang Philip O'Connell Stewart Jessamine Robert B. Elliott Takaaki Kobayashi Bernhard J. Hering 《Xenotransplantation》2016,23(1):14-24
Islet xenotransplantation represents an attractive solution to overcome the shortage of human islets for use in type 1 diabetes. The wide‐scale application of clinical islet xenotransplantation, however, requires that such a procedure takes place in a specifically and tightly regulated environment. With a view to promoting the safe application of clinical islet xenotransplantation, a few years ago the International Xenotransplantation Association (IXA) published a Consensus Statement that outlined the key ethical and regulatory requirements to be satisfied before the initiation of xenotransplantation studies in diabetic patients. This earlier IXA Statement also documented a disparate regulatory landscape among different geographical areas. This situation clearly fell short of the 2004 World Health Assembly Resolution WHA57.18 that urged Member States “to cooperate in the formulation of recommendations and guidelines to harmonize global practices” to ensure the highest ethical and regulatory standards on a global scale. In this new IXA report, IXA members who are active in xenotransplantation research in their respective geographic areas herewith briefly describe changes in the regulatory frameworks that have taken place in the intervening period in the various geographic areas or countries. The key reassuring take‐home message of the present report is that many countries have embraced the encouragement of the WHO to harmonize the procedures in a more global scale. Indeed, important regulatory changes have taken place or are in progress in several geographic areas that include Europe, Korea, Japan, and China. Such significant regulatory changes encompass the most diverse facets of the clinical application of xenotransplantation and comprise ethical aspects, source animals and product specifications, study supervision, sample archiving, patient follow‐up and even insurance coverage in some legislations. All these measures are expected to provide a better care and protection of recipients of xenotransplants but also a higher safety profile to xenotransplantation procedures with an ultimate net gain in terms of international public health. 相似文献
45.
First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 4: pre‐clinical efficacy and complication data required to justify a clinical trial 下载免费PDF全文
David K.C. Cooper Rita Bottino Pierre Gianello Melanie Graham Wayne J. Hawthorne Allan D. Kirk Olle Korsgren Chung‐Gyu Park Collin Weber 《Xenotransplantation》2016,23(1):46-52
In 2009, the International Xenotransplantation Association (IXA) published a consensus document that provided guidelines and “recommendations” (not regulations) for those contemplating clinical trials of porcine islet transplantation. These guidelines included the IXA's opinion on what constituted “rigorous pre‐clinical studies using the most relevant animal models” and were based on “non‐human primate testing.” We now report our discussion following a careful review of the 2009 guidelines as they relate to pre‐clinical testing. In summary, we do not believe there is a need to greatly modify the conclusions and recommendations of the original consensus document. Pre‐clinical studies should be sufficiently rigorous to provide optimism that a clinical trial is likely to be safe and has a realistic chance of success, but need not be so demanding that success might only be achieved by very prolonged experimentation, as this would not be in the interests of patients whose quality of life might benefit immensely from a successful islet xenotransplant. We believe these guidelines will be of benefit to both investigators planning a clinical trial and to institutions and regulatory authorities considering a proposal for a clinical trial. In addition, we suggest consideration should be given to establishing an IXA Clinical Trial Advisory Committee that would be available to advise (but not regulate) researchers considering initiating a clinical trial of xenotransplantation. 相似文献
46.
47.
Richard Mathieu 《Xenotransplantation》2016,23(4):258-268
48.
Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression 下载免费PDF全文
R. Aron Badin M. Vadori B. Vanhove V. Nerriere‐Daguin P. Naveilhan I. Neveu C. Jan X. Lévèque E. Venturi P. Mermillod N. Van Camp F. Dollé M. Guillermier L. Denaro R. Manara V. Citton P. Simioni P. Zampieri D. D'avella D. Rubello F. Fante M. Boldrin G. M. De Benedictis L. Cavicchioli D. Sgarabotto M. Plebani A. L. Stefani P. Brachet G. Blancho J. P. Soulillou P. Hantraye E. Cozzi 《American journal of transplantation》2016,16(7):2016-2029
Neural transplantation is a promising therapeutic approach for neurodegenerative diseases; however, many patients receiving intracerebral fetal allografts exhibit signs of immunization to donor antigens that could compromise the graft. In this context, we intracerebrally transplanted mesencephalic pig xenografts into primates to identify a suitable strategy to enable long‐term cell survival, maturation, and differentiation. Parkinsonian primates received WT or CTLA4‐Ig transgenic porcine xenografts and different durations of peripheral immunosuppression to test whether systemic plus graft‐mediated local immunosuppression might avoid rejection. A striking recovery of spontaneous locomotion was observed in primates receiving systemic plus local immunosuppression for 6 mo. Recovery was associated with restoration of dopaminergic activity detected both by positron emission tomography imaging and histological examination. Local infiltration by T cells and CD80/86+ microglial cells expressing indoleamine 2,3‐dioxigenase were observed only in CTLA4‐Ig recipients. Results suggest that in this primate neurotransplantation model, peripheral immunosuppression is indispensable to achieve the long‐term survival of porcine neuronal xenografts that is required to study the beneficial immunomodulatory effect of local blockade of T cell costimulation. 相似文献
49.
Rabea Hein Hendrik J. Sake Claudia Pokoyski Joachim Hundrieser Antje Brinkmann Wiebke Baars Monika Nowak‐Imialek Andrea Lucas‐Hahn Constanca Figueiredo Hans‐Joachim Schuberth Heiner Niemann Bjrn Petersen Reinhard Schwinzer 《American journal of transplantation》2020,20(4):988-998
Porcine xenografts lacking swine leukocyte antigen (SLA) class I are thought to be protected from human T cell responses. We have previously shown that SLA class I deficiency can be achieved in pigs by CRISPR/Cas9‐mediated deletion of β2‐microglobulin (B2M). Here, we characterized another line of genetically modified pigs in which targeting of the B2M locus did not result in complete absence of B2M and SLA class I but rather in significantly reduced expression levels of both molecules. Residual SLA class I was functionally inert, because no proper differentiation of the CD8+ T cell subset was observed in B2Mlow pigs. Cells from B2Mlow pigs were less capable in triggering proliferation of human peripheral blood mononuclear cells in vitro, which was mainly due to the nonresponsiveness of CD8+ T cells. Nevertheless, cytotoxic effector cells developing from unaffected cell populations (eg, CD4+ T cells, natural killer cells) lysed targets from both SLA class I+ wildtype and SLA class Ilow pigs with similar efficiency. These data indicate that the absence of SLA class I is an effective approach to prevent the activation of human CD8+ T cells during the induction phase of an anti‐xenograft response. However, cytotoxic activity of cells during the effector phase cannot be controlled by this approach. 相似文献
50.